Results 201 to 210 of about 601,516 (329)

Burden of Liver Disease Among Individuals With Turner Syndrome and Klinefelter Syndrome: A Comprehensive Perspective

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT The liver is increasingly recognized as a major regulator of systemic cardio‐renal‐metabolic health. Evidence is mounting that sex‐chromosome dosage per se itself, independent of gonadal sex hormones, modulates hepatic physiology and liver disease risk.
Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen   +2 more
wiley   +1 more source

Low-density lipoprotein cholesterol drives multinucleated giant cell formation in response to mycobacterium bovis Bacille Calmette-Guérin. [PDF]

Sci Rep
Merck PA, Lösslein AK, Neuber J, Schwer S, Jonas W, Pospisilik JA, Hilgendorf I, Henneke P, Lohrmann F.   +8 more
europepmc   +1 more source

Relativism and Low-Density Lipoprotein Cholesterol

Journal of the American College of Cardiology, 2017
Cian P. McCarthy, John W. McEvoy
openaire   +1 more source

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Archives of Internal Medicine, 2000
T. Pearson, Irene Laurora, H. Chu, S. Kafonek   +3 more
semanticscholar   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Risk for coronary artery disease among individuals with normal low-density lipoprotein cholesterol (LDL-C) levels. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Shi Z, Mulford AJ, Wei J, Tran H, Ashworth A, Zheng SL, Helfand BT, Duggan D, Dunnenberger HM, Hulick PJ, Davidson DJ, Qamar A, Sanders AR, Xu J.   +13 more
europepmc   +1 more source

Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile.

Journal of the American Medical Association (JAMA), 2013
S. Martin, M. Blaha, M. Elshazly, P. Toth, P. Kwiterovich, R. Blumenthal, S. Jones   +6 more
semanticscholar   +1 more source

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Clinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park, Jae‐Hwan Lee, Jin‐Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong‐Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin‐Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung‐Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo‐Soo Kim, Moo Hyun Kim, Do‐Sun Lim, Eun‐Seok Shin, Paul A. Gurbel, Young‐Hoon Jeong, on behalf of the PTRG‐DES Consortium Investigators   +22 more
wiley   +1 more source

Risk of Retinal Vascular Occlusive Disease According to Type and Low-Density Lipoprotein-Cholesterol Control after Acute Coronary Syndrome. [PDF]

Yonsei Med J
Kim M, Lee JH, Cho YH, Bae K, Lee JY.
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source